CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
AI 驱动 CAR-T 细胞治疗面向实体瘤的策略
英文原题：Strategies of AI-Driven CAR-T Cell Therapy Towards Solid Tumours.
查看英文原题
Strategies of AI-Driven CAR-T Cell Therapy Towards Solid Tumours.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞免疫疗法在血液系统恶性肿瘤中取得显著成功，但在实体瘤中仍面临肿瘤微环境（TME）抑制和抗原异质性等关键挑战，凸显了开发有效且安全CAR产品的迫切需求。将人工智能（AI）整合至CAR-T 细胞免疫疗法中，为提高治疗效力带来重要机遇。本文重点介绍AI在解决阻碍CAR-T 治疗实体瘤的主要难题方面的变革性作用，包括辅助CAR设计和生产流程、发现新的CAR靶向基因，以及检测实体瘤中的细胞异质性。我们对利用AI驱动策略增强CAR-T 细胞在TME中的持久性、迁移和可视化能力持乐观态度。此外，本文还讨论了推进AI驱动CAR-T 细胞疗法的当前挑战和前景。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T cell immunotherapy shows significant success in hematologic malignancies.
However, it faces critical challenges in solid tumours, such as suppressive tumour microenvironment (TME) and antigenic heterogeneity, highlighting the urgent need for effective and safe CAR products. The integration of artificial intelligence (AI) into CAR-T cell immunotherapy offers exceptional opportunities to improve its therapeutic efficacy.
More specifically, this paper highlights the transformative role of AI in addressing key challenges that impede the success of CAR-T cell therapy in solid tumours, including assisting in CAR design and manufacturing process, identifying novel CAR-targeted genes, and detecting cell heterogeneity in solid tumours.
We remain optimistic about AI-driven strategies for enhancing CAR T-cell persistence, trafficking, and visualisation in the TME.
In addition, we highlight the current challenges and prospects for advancing AI-driven CAR-T cell therapies.
论文信息
- 作者
- Abdalla AME、Miao Y、Taha YA、Meng N、Ouyang C
- 第一作者单位
- School of Biological Sciences and Technology, University of Jinan, Jinan, China.China
- 通讯作者单位
- Department of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.China
- 文献类型
- 综述
- 期刊
- Immunology2026 Jul
- 原文标识
- PubMed 41709747 · DOI 10.1111/imm.70124